Clinical Trials · NCT05760313

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

CompletedPhase 2Linaclotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
AbbVie
Enrollment
19
Start date
Apr 2023
Locations
38 sites, 7 countries
Primary endpoint
Change From Baseline in Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Study Intervention Period
View Linaclotide compound reference